Literature DB >> 1851987

Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels.

C Robaut1, F Mondon, J Bandet, F Ferre, I Cavero.   

Abstract

High-affinity binding sites for [125I]endothelin(ET)-1 have been detected in purified membrane preparations of the fetal arteries and veins of the chorionic plate and the stem villi vessels of the human term placenta. Regardless of the vessel type, the apparent dissociation constant was found to be in the picomolar range (26----45 pM), and the Bmax value close to 600 fmol/mg protein. In stem villi vessels, ET-1, ET-2, sarafotoxin S6b and vasocontractor intestinal peptide (VIC) were approximately equipotent in their competitive displacement of [125I]ET-1 binding. The endothelin precursors, human and porcine big-endothelin, recognized ET-1 sites with low affinity (nM range), a finding which reflects their low potency as recognized vasocontractant agents. Interestingly, [125I]ET-1 binding parameters and pharmacological profiles were identical in fetal veins and arteries of the chorionic plate. Similarly, a study carried out in rat aortic membranes, revealed the presence of high affinity [125I]ET-1 binding sites with pharmacological characteristics close to those of the human stem villi vessels. In all vessels investigated, the binding pattern of ET-3 against [125I]ET-1 was of a non-competitive nature. Thus, these results demonstrate the presence of specific [125I]ET-1 binding sites along the vascular tree of the fetal side of the placenta and would support evidence currently available, favouring the existence of distinct ET-1 and ET-3 receptors. Finally, ET-1 in the human placenta may play an important physiological role as regulator of vascular resistance and/or be implicated as a pathological factor in certain pregnancy-related diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851987     DOI: 10.1016/0143-4004(91)90510-m

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  6 in total

1.  Differential localization of endothelin ETA and ETB binding sites in human placenta.

Authors:  R A Rutherford; J Wharton; A McCarthy; L Gordon; M H Sullivan; M G Elder; J M Polak
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

2.  Cross tachyphylaxis to endothelin isopeptide-induced hypotension: a phenomenon not seen with proendothelin.

Authors:  A C Le Monnier de Gouville; I Cavero
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

3.  Localization and production of immunoreactive endothelin-1 in the trophoblast of human placenta.

Authors:  A Malassiné; L Cronier; F Mondon; T M Mignot; F Ferré
Journal:  Cell Tissue Res       Date:  1993-03       Impact factor: 5.249

4.  Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries.

Authors:  S Sabry; F Mondon; M Levy; F Ferré; A T Dinh-Xuan
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

5.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Differential regional fatty acid distribution in normotensive and preeclampsia placenta.

Authors:  Alka Rani; Preeti Chavan-Gautam; Savita Mehendale; Girija Wagh; Sadhana Joshi
Journal:  BBA Clin       Date:  2015-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.